Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Neurology

Treatment Strategy & Standard of Care

At a Glance

Treatment for atypical Rett variants like CDD and FOXG1 syndrome focuses on symptom management rather than a cure. Care teams use targeted therapies like Ztalmy for seizures, combined with specialized support for digestion, sleep, and communication using AAC devices.

While there is currently no “cure” for atypical Rett variants, the medical landscape has shifted from simply watching symptoms to actively managing them with new, targeted therapies [1][2]. Management is a “marathon, not a sprint,” requiring a multidisciplinary team to address the brain, the gut, and the daily quality of life for your child [3][4].

Clarifying Targeted FDA-Approved Treatments

In recent years, two significant medications have been approved, but it is critical to understand exactly which conditions they are approved for, as they are not interchangeable:

  • Trofinetide (Daybue): This is FDA-approved specifically for Rett syndrome (which is primarily associated with MECP2 mutations) in adults and children ages 2 and older [1][5]. It is NOT currently indicated or approved for CDKL5 Deficiency Disorder (CDD) or FOXG1 Syndrome [6][7]. For patients with MECP2-related Rett, it showed improvements in core symptoms like communication and hand use [7][8].
  • Ganaxolone (Ztalmy): This medication is FDA-approved specifically for the treatment of seizures associated with CDKL5 Deficiency Disorder (CDD) in patients 2 years and older [2][9]. It works by modulating GABA receptors in the brain to help calm the “electrical storms” that cause seizures [10][11].

Seizure Management: A Primary Focus

For children with CDD and FOXG1 syndrome, managing intractable seizures (seizures that don’t respond well to standard drugs) is often the top priority [12][13].

  • Medication Rotation: Doctors often try various anti-seizure medications (ASMs) such as clobazam or valproic acid [12][13].
  • Ketogenic Diet: This high-fat, low-carbohydrate diet is frequently used as an effective non-drug intervention to help reduce seizure frequency [14][15].
  • Vagus Nerve Stimulation (VNS): A small device implanted under the skin can send regular electrical pulses to the brain to help stabilize electrical activity [16].

🚨 Emergency Warning Signs: Ask your doctor for a specific “rescue plan.” You must seek emergency medical care if your child exhibits signs of status epilepticus (a seizure lasting more than 5 minutes, or back-to-back seizures without recovery), severe respiratory distress, or signs of aspiration pneumonia.

Managing the “Whole Child”

Beyond the brain, “non-neurological” symptoms can be some of the most challenging for families to navigate daily:

  1. Gastrointestinal (GI) & Feeding: Many children struggle with severe constipation, reflux, or difficulty swallowing (dysphagia) [17][18]. Management often includes specialized diets, stool softeners, or the placement of a feeding tube (G-tube) to ensure proper nutrition [19][4].
  2. Sleep Disorders: Sleep-wake reversals and frequent night waking are common [20]. First-line management includes “sleep hygiene” (routines and environment), while some doctors may recommend melatonin to help regulate the sleep cycle [21][22].
  3. Physical and Occupational Therapy: Intensive, regular therapy is essential to manage muscle tone (hypotonia) and prevent joint stiffness [23][3].
  4. Augmentative and Alternative Communication (AAC): Because severe language deficits are nearly universal, early evaluation for AAC—including eye-gaze technology—is a critical pillar of care. This technology can give your child a vital voice, even if they cannot speak verbally [3].

The Horizon: Gene Therapy

We are currently in an era of rapid research. Scientists are working on gene therapies—treatments that aim to deliver a healthy copy of a gene (like CDKL5 or FOXG1) directly to the brain cells [24][25]. Participating in natural history studies and patient registries is one of the best ways for families to stay connected to these future opportunities [26][27].

Common questions in this guide

Is Daybue (Trofinetide) approved for atypical Rett variants like CDD or FOXG1?
No. Trofinetide (Daybue) is currently FDA-approved specifically for Rett syndrome associated with MECP2 mutations. It is not approved or indicated for CDKL5 Deficiency Disorder or FOXG1 syndrome.
How are severe seizures managed in atypical Rett syndrome?
When standard medications fail, doctors may prescribe targeted drugs like Ztalmy for CDD-related seizures. Non-drug interventions, including the ketogenic diet or an implanted vagus nerve stimulation (VNS) device, are also highly effective options.
What other symptoms need to be managed besides seizures?
Beyond seizures, children often face severe gastrointestinal problems like constipation, reflux, and difficulty swallowing. Sleep disruptions and low muscle tone are also very common and require a coordinated care team to manage.
How can my child communicate if they cannot speak verbally?
Augmentative and Alternative Communication (AAC) is a vital tool for children with severe language deficits. Early evaluation for eye-gaze technology can give your child a reliable way to express themselves, even without verbal speech.
When should I seek emergency medical care for my child's seizures?
You should go to the emergency room immediately if your child experiences status epilepticus, which is a single seizure lasting more than 5 minutes or multiple back-to-back seizures without recovery. Severe breathing distress also requires immediate care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my child's specific gene mutation, which FDA-approved therapies are they officially indicated for?
  2. 2.What is the current step-by-step approach we should take if my child's seizures become 'refractory' (difficult to treat)?
  3. 3.Can you refer us for an Augmentative and Alternative Communication (AAC) evaluation to explore eye-gaze technology?
  4. 4.What specific emergency warning signs for respiratory distress or status epilepticus should prompt us to go to the ER immediately?
  5. 5.Are there any active clinical trials or natural history studies for my child's specific mutation that we should join?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

    Neul JL, Percy AK, Benke TA, et al.

    Nature medicine 2023; (29(6)):1468-1475 doi:10.1038/s41591-023-02398-1.

    PMID: 37291210
  2. 2

    Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.

    Olson HE, Amin S, Bahi-Buisson N, et al.

    Epilepsia 2024; (65(1)):37-45 doi:10.1111/epi.17826.

    PMID: 37950390
  3. 3

    Evidence-Based Physical Therapy for Individuals with Rett Syndrome: A Systematic Review.

    Fonzo M, Sirico F, Corrado B

    Brain sciences 2020; (10(7)) doi:10.3390/brainsci10070410.

    PMID: 32630125
  4. 4

    International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.

    Amin S, Monaghan M, Aledo-Serrano A, et al.

    Frontiers in neurology 2022; (13()):874695 doi:10.3389/fneur.2022.874695.

    PMID: 35795799
  5. 5

    Trofinetide: First Approval.

    Keam SJ

    Drugs 2023; (83(9)):819-824 doi:10.1007/s40265-023-01883-8.

    PMID: 37191913
  6. 6

    Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.

    Hudu SA, Elmigdadi F, Qtaitat AA, et al.

    Journal of clinical medicine 2023; (12(15)) doi:10.3390/jcm12155114.

    PMID: 37568516
  7. 7

    Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.

    Percy AK, Neul JL, Benke TA, et al.

    Med (New York, N.Y.) 2024; (5(9)):1178-1189.e3 doi:10.1016/j.medj.2024.05.018.

    PMID: 38917793
  8. 8

    Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials.

    Barrett AM, Olayinka-Amao O, Martin S, et al.

    Clinical therapeutics 2025; (47(3)):181-188 doi:10.1016/j.clinthera.2024.12.012.

    PMID: 39824747
  9. 9

    Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder.

    Hoy SM

    Paediatric drugs 2025; (27(1)):111-118 doi:10.1007/s40272-024-00670-6.

    PMID: 39792341
  10. 10

    Ganaxolone: First Approval.

    Lamb YN

    Drugs 2022; (82(8)):933-940 doi:10.1007/s40265-022-01724-0.

    PMID: 35596878
  11. 11

    Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

    Devinsky O, Verducci C, Thiele EA, et al.

    Epilepsy & behavior : E&B 2018; (86()):131-137 doi:10.1016/j.yebeh.2018.05.013.

    PMID: 30006259
  12. 12

    Antiseizure medications in CDKL5 encephalopathy- systematic review.

    Kalinowska-Doman A, Strzelczyk A, Paprocka J

    Seizure 2025; (131()):391-396 doi:10.1016/j.seizure.2025.08.002.

    PMID: 40834685
  13. 13

    Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.

    Olson HE, Daniels CI, Haviland I, et al.

    Journal of neurodevelopmental disorders 2021; (13(1)):40 doi:10.1186/s11689-021-09384-z.

    PMID: 34530725
  14. 14

    The Ketogenic Diet: An Underrecognized Therapy for Rett Syndrome.

    Haridas B, Bessone S, Turner Z, Kossoff E

    Journal of child neurology 2025; (40(7)):530-534 doi:10.1177/08830738251329139.

    PMID: 40208081
  15. 15

    Validating the Rett Syndrome Gross Motor Scale.

    Downs J, Stahlhut M, Wong K, et al.

    PloS one 2016; (11(1)):e0147555 doi:10.1371/journal.pone.0147555.

    PMID: 26800272
  16. 16

    Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.

    Lim Z, Wong K, Downs J, et al.

    Epilepsy research 2018; (146()):36-40 doi:10.1016/j.eplepsyres.2018.07.013.

    PMID: 30071384
  17. 17

    Gut microbiota profile in CDKL5 deficiency disorder patients.

    Borghi E, Xynomilakis O, Ottaviano E, et al.

    Scientific reports 2024; (14(1)):7376 doi:10.1038/s41598-024-56989-0.

    PMID: 38548767
  18. 18

    CDKL5 deficiency causes epileptic seizures independent of cellular mosaicism.

    Takahashi S, Takeguchi R, Tanaka R, et al.

    Journal of the neurological sciences 2022; (443()):120498 doi:10.1016/j.jns.2022.120498.

    PMID: 36417806
  19. 19

    Parent/caregiver perspectives of meaningful improvement in functional domains for people with CDKL5 deficiency disorder: a mixed-methods study.

    Keeley J, Skoda Z, Utley K, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2025; (34(12)):3609-3620 doi:10.1007/s11136-025-04048-0.

    PMID: 40924387
  20. 20

    Modification of a parent-report sleep scale for individuals with CDKL5 deficiency disorder: a psychometric study.

    Saldaris JM, Demarest S, Jacoby P, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2024; (20(12)):1887-1893 doi:10.5664/jcsm.11244.

    PMID: 38963064
  21. 21

    Sleep disorders in children: classification, evaluation, and management. A review.

    Gemke RJBJ, Burger P, Steur LMH

    European journal of pediatrics 2024; (184(1)):39 doi:10.1007/s00431-024-05822-x.

    PMID: 39579198
  22. 22

    Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses.

    Choi K, Lee YJ, Park S, et al.

    Sleep medicine reviews 2022; (66()):101692 doi:10.1016/j.smrv.2022.101692.

    PMID: 36179487
  23. 23

    A New Scale to Evaluate Motor Function in Rett Syndrome: Validation and Psychometric Properties.

    Rodocanachi Roidi ML, Isaias IU, Cozzi F, et al.

    Pediatric neurology 2019; (100()):80-86 doi:10.1016/j.pediatrneurol.2019.03.005.

    PMID: 31047758
  24. 24

    A cross-correction gene therapy approach for CDKL5 deficiency disorder improves the pathological phenotype of CDD patient-derived cortical organoids.

    Medici G, Bove AM, Trazzi S, et al.

    Frontiers in bioengineering and biotechnology 2025; (13()):1744903 doi:10.3389/fbioe.2025.1744903.

    PMID: 41647608
  25. 25

    AAV-mediated neuronal expression of FOXG1 restores oligodendrocyte maturation, myelination, and hippocampal structure in mouse models of FOXG1 syndrome.

    Park J, O'Shea H, Jeon S, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.64898/2025.12.04.692422.

    PMID: 41573856
  26. 26

    AAV-mediated FOXG1 gene editing in human Rett primary cells.

    Croci S, Carriero ML, Capitani K, et al.

    European journal of human genetics : EJHG 2020; (28(10)):1446-1458 doi:10.1038/s41431-020-0652-6.

    PMID: 32541681
  27. 27

    Longitudinal characterization of clinical, developmental, and behavioral phenotypes in 101 children and adults with FOXG1 syndrome.

    Brimble E, Ventola P, Blomenberg E, et al.

    Journal of neurodevelopmental disorders 2025; (17(1)):64 doi:10.1186/s11689-025-09653-1.

    PMID: 41136907

This information about atypical Rett syndrome treatments is for educational purposes only. Always consult your child's pediatric neurologist or multidisciplinary care team before making changes to their care plan.

Get notified when new evidence is published on Atypical Rett syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.